Bone marrow cellularity and progenitor content in mice treated with TMTX and either NBMPR-P or draflazine. C57Bl/6J mice were treated for 5 consecutive days with either TMTX 130 mg/kg/d, NBMPR-P 20 mg/kg/d, draflazine 20 mg/kg/d, or with combinations of either TMTX (130 mg/kg/d) plus NBMPR-P (20 mg/kg/d) or TMTX (130 mg/kg/d) plus draflazine (20 mg/kg/d of racemic mixture). Twenty-four hours after the final treatment, the femurs were flushed to determine both total cellularity and progenitor content per femur. All values are expressed as percentages relative to untreated mice. Each bar represents the mean ±1 SD of three independent experiments. Each experiment contained two to three mice per group.